Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni L Ceresoli

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2006
Phase II study of pemetrexed plus carboplatin in malignant pleural mesotheliomaGiovanni L Ceresoli, Paolo A Zucali, Adolfo G Favaretto, et al.
The Lancet. Oncology|October 20, 2019
Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trialGiovanni L Ceresoli, Joachim G Aerts, Rafal Dziadziuszko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2005
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patientsFederico Cappuzzo, Marileila Varella-Garcia, Hisayuki Shigematsu, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2012
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesotheliomaJaine K Blayney, Giovanni L Ceresoli, Bruno Castagneto, et al.
Journal of the National Cancer Institute|May 5, 2005
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancerFederico Cappuzzo, Fred R Hirsch, Elisa Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesotheliomaVanesa Gregorc, Paolo A Zucali, Armando Santoro, et al.
The Lancet. Respiratory Medicine|May 20, 2019
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trialGiorgio V Scagliotti, Rabab Gaafar, Anna K Nowak, et al.
JAMA Oncology|February 15, 2024
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical TrialPeter W Szlosarek, Benjamin C Creelan, Thomas Sarkodie, et al.
The Lancet. Oncology|March 31, 2022
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trialHedy L Kindler, Silvia Novello, Alessandra Bearz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2022
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT RegistryJennifer G Whisenant, Javier Baena, Alessio Cortellini, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2006
Phase II study of pemetrexed plus carboplatin in malignant pleural mesotheliomaGiovanni L Ceresoli, Paolo A Zucali, Adolfo G Favaretto, et al.
The Lancet. Oncology|October 20, 2019
Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trialGiovanni L Ceresoli, Joachim G Aerts, Rafal Dziadziuszko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2005
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patientsFederico Cappuzzo, Marileila Varella-Garcia, Hisayuki Shigematsu, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2012
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesotheliomaJaine K Blayney, Giovanni L Ceresoli, Bruno Castagneto, et al.
Journal of the National Cancer Institute|May 5, 2005
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancerFederico Cappuzzo, Fred R Hirsch, Elisa Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesotheliomaVanesa Gregorc, Paolo A Zucali, Armando Santoro, et al.
The Lancet. Respiratory Medicine|May 20, 2019
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trialGiorgio V Scagliotti, Rabab Gaafar, Anna K Nowak, et al.
JAMA Oncology|February 15, 2024
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical TrialPeter W Szlosarek, Benjamin C Creelan, Thomas Sarkodie, et al.
The Lancet. Oncology|March 31, 2022
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trialHedy L Kindler, Silvia Novello, Alessandra Bearz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2022
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT RegistryJennifer G Whisenant, Javier Baena, Alessio Cortellini, et al.
Pageof 2